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ABSTRACT. Screening instruments are ideal for acute clinical settings because they are easy to apply, fast, inexpensive 
and sensitive for specific samples. However, there is a need to verify the psychometric properties of screening in 
stroke patients. Objective: This study investigated the psychometric properties (methodological procedures) of cognitive 
screening for patients with cerebrovascular diseases. Methods: A systematic review of papers published on PsycINFO, Web 
of Knowledge, PubMed and Science Direct (2005 to 2016) was performed. Results: A total of 55 articles remained after 
applying exclusion criteria. The samples ranged from 20 to 657 patients. Most articles evaluated elderly individuals with 
four to 13 years of education who had experienced ischemic or hemorrhagic stroke. There was a tendency to find evidence 
of validity for criteria and to analyze the sensitivity/specificity of the instruments. Although the studies frequently used the 
Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) to seek evidence of validity and 
reliability, the use of these instruments among stroke patients has been criticized due to their psychometric properties 
and the neuropsychological functions evaluated. Conclusion: Although there is no gold standard screen for assessing 
adults post-stroke, instruments devised specifically for this population have shown promise. This review helps both 
researchers and clinicians to select the most appropriate screen for identifying cognitive impairment in adults post-stroke.
Key words: neuropsychological assessment, stroke, vascular cognitive impairment, validity, reliability.
PROPRIEDADES PSICOMÉTRICAS DE TRIAGENS COGNITIVAS NAS DOENÇAS CEREBROVASCULARES: UMA REVISÃO SISTEMÁTICA
RESUMO. Instrumentos de triagem são ideias no contexto clínico hospitalar, uma vez que são fáceis de administrar, 
rápidos, tem baixo custo e são sensíveis para amostras específicas. Portanto, há a necessidade de se verificar as 
propriedades psicométricas de instrumentos de triagem para pacientes pós acidente vascular cerebral. Objetivo: Este 
estudo investigou as propriedades psicométricas (procedimentos metodológicos) de triagens cognitivas para pacientes 
com doenças cerebrovasculares. Métodos: Foi realizada uma revisão sistemática de artigos publicados em PsycINFO, 
Web of Knowledge, PubMed e Science Direct (2005 a 2016). Apenas 55 artigos permaneceram após a aplicação 
dos critérios de exclusão. Resultados: As amostras variaram de 20 a 657 pacientes; a maioria dos artigos avaliou 
indivíduos idosos, com quatro a 13 anos de educação, que sofreram AVC isquêmico e hemorrágico. Houve uma 
tendência para encontrar evidências de validade relacionadas ao critério e analisar a sensibilidade/especificidade 
dos instrumentos. Embora os estudos frequentemente apliquem o Mini Exame do Estado Mental (MMSE) e o Montreal 
Cognitive Assessment (MoCA) para buscar evidências de validade e de fidedignidade, o uso desses instrumentos em 
pacientes com AVC é criticado por razões relacionadas às suas propriedades psicométricas e funções neuropsicológicas 
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avaliadas. Conclusão: Embora não exista uma triagem padrão-ouro para avaliação de adultos pós-AVC, os instrumentos 
construídos especificamente para esta população mostraram-se promissores. Este estudo de revisão contribui tanto aos 
pesquisadores quanto aos clínicos que desejam selecionar o rastreio mais apropriado para identificar comprometimento 
cognitivo em adultos pós-AVC.
Palavras-chave: avaliação neuropsicológica, acidente vascular cerebral, comprometimento cognitivo vascular, validade, 
fidedignidade.
Cognitive impairment is a common consequence fol-lowing stroke, occurring in approximately 45% to 
83% of subjects depending on the follow-up time, neu-
rological characteristics and instruments used.1,2 Nota-
bly, cognitive impairment is observed in more than 50% 
of patients six months after stroke.2,3 These patients can 
develop vascular dementia, which affects both func-
tional independence and quality of life.4-6 
The most common deficits in vascular cognitive 
impairment include reduced processing speed, execu-
tive dysfunction, hemineglect, inattention, aphasia, 
apraxia and amnesia.3,5,7 There is no consensus on which 
tests should be used to evaluate performance on these 
functions in post-stroke patients.8 The selection of tools 
usually depends on an instrument’s availability and on 
the neuropsychologist’s preference and familiarity with 
the tasks.9 
Using an extensive battery of neuropsychological 
assessment is impractical in many clinical settings, 
where evaluation with simpler cognitive screening 
instruments is required.9 Screening instruments are 
therefore ideal for an acute clinical setting because they 
are easy to apply, fast, inexpensive and sensitive for 
specific samples.10,11 Ideally, neuropsychologists should 
be aware of whether the selected screen has adequate 
psychometric properties for stroke populations in their 
countries. However, most neuropsychologists have 
based their diagnosis on instruments psychometrically 
tested in patients with nonvascular cognitive impair-
ment.6,12-14 The Neuropsychological Working Group of 
the National Institute of Neurological Disorders and 
Stroke (NINDS) and the Canadian Stroke Network 
(CSN) have recommended three protocols (60, 30, and 
5 minute protocols) for assessing vascular cognitive 
impairment,15 and their psychometric properties have 
been tested in many studies.16-20
Regarding the instruments’ psychometric properties, 
neuropsychological tests should exhibit evidence of spe-
cific forms of validity: evidence based on test content, 
evidence based on response processes, evidence regard-
ing internal structure (dimensionality and relationships 
between scores of the same test), evidence regarding 
relationships with conceptually related constructs (con-
vergent and discriminant evidence), evidence regarding 
relationships with criteria (contrasting groups, effect 
size, concurrent and predictive validity), and evidence 
based on the consequences of testing. In addition, it is 
important for the tests to demonstrate reliability in the 
form of temporal stability and internal consistency.21
Furthermore, the instrument should be constructed 
in a manner that aims to determine cognitive deficits 
in a specific population. Thus, we recognize the need 
to verify the psychometric properties of screening in 
stroke patients. In this context, the present systematic 
review aims to identify the cognitive screening with 
adequate psychometric properties for use in stroke 
patient samples. The specific aims of this review study 
were: (a) to analyze the quality of the methodological 
information reported (sample size, age and education 
of participants, neurological data such as cerebrovas-
cular disease and time post-stroke); and (b) to identify 
cognitive screening that have adequate validity and 
reliability evidence. This systematic review reports the 
methodological limitations of psychometric studies of 
adults post-stroke and investigates which screening 
are most adequate for identifying cognitive deficits 
in these patients. This review article can be distin-
guished from other studies in this field that tend to 
discuss only the sensitivity and specificity of screen-
ing instruments22,23 or fail to examine the psychomet-
ric properties of the tests in stroke patient samples.8
METHODS
We performed a systematic review of papers published 
from January 2005 to December 2016 on the following 
databases: PsycINFO (refined by the terms in the 
abstract), Web of Knowledge (refined by the terms in 
the subject of the article), PubMed (refined to include 
the terms in the title and abstract), and Science Direct 
(refined by the terms in the abstract, title, or keywords). 
The refinements varied because the databases use 
different advanced search tools. The following combina-
tions of keywords were applied: “stroke”, “cerebrovas-
cular accident”, “vascular cognitive impairment”, and 
“cerebrovascular disease” versus “neuropsychological 
assessment”, “neuropsychological evaluation”, “cogni-
tive screening”, “neuropsychological screening”, “cogni-
tive assessment”, and “cognitive evaluation”. These 
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N = 980
























Figure 1. Studies selection 
process flowchart.
keywords were selected from the most commonly used 
terms in the health databases to include all articles 
that reported neuropsychological evaluations in stroke 
patients.
After excluding repeated articles, the remaining 
articles were divided and analyzed by two judges. Four 
judges selected only empirical studies in English, Portu-
guese, French or Spanish that assessed adults with cere-
brovascular disease using cognitive screening. If the two 
judges disagreed on the selection of a particular study, a 
third judge was recruited. The judges had experience in 
neuropsychological assessment post-stroke and knowl-
edge about the instruments used. 
Many studies have evaluated neuropsychological 
deficits in stroke patients with cognitive screening tests, 
but failed to explicitly report that their analysis was psy-
chometric. In these situations, we assumed that these 
articles claimed to analyze validity evidence based on 
relations to other variables.21
RESULTS
After performing searches and excluding repeated arti-
cles, 74 studies that evaluated neuropsychological func-
tions in stroke groups using screening instruments were 
selected. These articles were read in full, with a focus 
on the methods and results sections. Subsequently, 19 
non-psychometric studies were excluded (Figure 1). The 
results and discussion will be presented in two sections: 
(1) characteristics of the samples; and (2) psychometric 
properties of the cognitive screening. 
Characteristics of the samples
In our review, the samples ranged from 20 to 657 stroke 
patients, but only one study calculated the sample size.24 
Most of the articles evaluated individuals between 50 
and 80 years old (Table 1), and only two studies included 
younger samples (i.e., patients under 30 years of age).25,26 
The majority of the studies evaluated patients with four 
to 13 years of education (9 years on average). However, 
27.27% of the articles did not specify the educational 
levels of the participants (Table 1).  With respect to cere-
brovascular disease, 30.90% of studies evaluated isch-
emic and hemorrhagic stroke samples, 21.81% evalu-
ated transient ischemic attack (TIA) and stroke patients, 
10.90% ischemic stroke only, 9.09% cerebral small vessel 
diseases, 7.27% hemorrhagic stroke, 3.63% vascular 
dementia and 16.36% did not report this information 
(Table 1). The time between post-stroke onset and 
neuropsychological assessment varied. A total of 50.90% 
of studies assessed patients at 3 months post-stroke, 
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Years of education 
(M±SD, % or range) Time post-stroke
Addenbrooke’s Cognitive  
Examination-Revised (ACE-R)13
101 (NI) 67.0–82.5 9.0–11.0 8-48 days
Barrow Neurological Institute Screen  
for Higher Cerebral Functions (BNIS)27 
54 (I, H, SH) 53.8±12.3 33.3% high education 15.0±12.8 weeks
BNIS28  295 (I) 43.4-66 92 < 9; 203 > 9 7 years
Birmingham Cognitive Screen  
(BCoS – Cantonese version)29 
98 (I) >50 years NI 2 weeks
Birmingham Cognitive Screen (BCoS)30 657 (I and H) 69.31±14.34, 
71.38±12.60
11.52±2.76, 11.19±2.76 26.65±22.36, 20.44±17.29
Brief Memory and Executive Test (BMET)31 196 (SVD) 63.5±9.9 13.7±3.8 20.5±32.3 months
Brief Neuropsychological Screening (BNS)32 134 (NI) 69.7±12.9 8.3±3.4 <1 month
Clock Drawing Test (CDT)7 49 (I, IH, SH) 62±53.5 NI 38±17 days
CDT33 187 (I and H) 49 - 80 0 - 29 3 - 25 months
Cog-434 92 (I and TIA) 63-83 NI 1-4 days
Cognistat7 49 (I, IH, SH) 62±53.5 NI 38±17 days
Cognitive Assessment Scale for  
Stroke Patients (CASP)35 
44 (I and H) 64±15 NI 42±22 days
CASP36 50 (I and H) 63±14 NI 40±17 days
Functional Independence Measure  
(FIM cognitive)37 
169 (I and H) 56.2±11.3 61.2% intermediate <12 months
Middlesex Elderly Assessment of  
Mental State (MEAMS)38
30 (NI) 75.8±7.94 NI 20.73±24.37 days
Mild Vascular Cognitive Impairment Assessment 
tool for Stroke (MVCI)39
60 (I and H) 64.07±13.46 NI NI
Mini-Mental State Examination (MMSE)6 34 (I and H) 64.7±11.5 1 – 7 6.5±2.9 days
MMSE37 169 (I and H) 56.2±11.3 61.2% intermediate <12 months
MMSE40 493 (TIA, I and H) 69.9±12.4 NI 6 months or 5 years
MMSE41 80 (MI, SVD) 65.85±6.94 10.00±3.35 3 months
MMSE42 239 (TIA and I) 60.2±11.8 7.5±4.1 3-6 months
MMSE43 327 (TIA and I) 59.8±11.6 7.7±4.3 3-6 months
MMSE24 60 (I and IH) 72.1±13.9 10.5±3.9 98.3±12.0 days
MMSE44 388 (I and TIA) 59.8±11.6 7.7±4.3 0-14 days, 3-6 months
MMSE45 138 (SIVD) 50-85 > 6 > 3 months
MMSE46 105 (I) 68.61±10.35 8.90±4.24 < 2 weeks
MMSE16 83 (I and H) 66.6±9.7 9.2±4.8 9.0±5.4 months
Montreal Cognitive Assessment (MoCA)43 327 (TIA and I) 59.8±11.6 7.7±4.3 3-6 months
MoCA47 29 (I, H, TIA) 68±12 NI 2.5±1.4 days
MoCA48 95 (I and H) 68.2±13.7 79% primary 6.6±3.5
MoCA20 34 (VD) 73.21±7.85 4.97±2.74 NI
MoCA42 239 (TIA and I) 60.2±11.8 7.5±4.1 3-6 months
continues.
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Years of education 
(M±SD, % or range) Time post-stroke
MoCA14 99 (TIA and stroke) 73.4±11.6 63% < 12 1 year
MoCA24 60 (I and IH) 72.1±13.9 10.5±3.9 98.3±12.0 days
MoCA49 80 (I and H) 68.2±14.6 9.2±4.4 5-9 days, 8.4±2.2 months
MoCA44 388 (I and TIA) 59.8±11.6 7.7±4.3 0-14 days, 3-6 months
MoCA12 136 (I and H) 64.3±14.3 NI 11.1±14.5 days
MoCA25 108 (aSAH) 21-75 NI 2–4 weeks, 1 year
MoCA26 194 (aSAH) 21-75 NI 1 year
MoCA45 138 (SIVD) 50-85 > 6 > 3 months
MoCA50 211 (I and H) 70.6±1.8 23/98/42 (low/medium/ high) 5.1±4.9 days
MoCA18 291 59.8±11.6 7.7±4.3 3-6 months, 1 year
MoCA46 105 (I) 68.61±10.35 8.90±4.24 < 2 weeks
miniMoCA51 72 (NI) 68.1±15 11.2±2 NI
MoCA (by telephone)52 91 (I, H, TIA) 72.9±11.6 63% <12 3.1±1.9 years
MoCA BM (Bahasa Malaysia version)53 40 (I and H) 57.2±10.3 8.5±3.9 164-581 days
MoCA Beijing version54 102 (I and TIA) 53.95±11.43 12/74/26 (low/medium/ high) > 14 days
MoCA Beijing version (by telephone)19 89 (NI) 62.9±8.6 9.2±4.2 > 3 months
MoCA (Changsha)55 338 (I and VD) > 40 years > 2 NI
MoCA (Chinese – Cantonese)56 70 (VD) 70.1±7.88 8.84±3.20 3 months
MoCA (Chinese – Cantonese)57 a) 74, b) 80 (aSAH) a) 49–66, b) 47–61 NI a) 2–7 weeks, b) 1 year





Hong Kong MoCA (HK-MoCA)59 90 (aSAH) 54.0±11.0 NI 3 months
HK-MoCA57 50 (I) 68.8±9.2 5.9±4.1 6–18 months
HK-MoCA (by telephone)60 104 (I, H, and TIA) 68.9±10.1, 70.8±9.2 6.3±4.4, 6.0±4.5 39.4±7.6 months
HK-MoCA61 40 (SMD) 70.08±8.5 5.98±4.5 < 3 months
MoCA (Singaporean)62 100 (TIA, I and H) 61.2±11.3 52% ≤ primary 4.2±2.4 days
Northwick Park Examination  
of Cognition (NPEC)63
166 (NI) 69.2±14.1 NI 5.6±7.9 days
Oxford Cognitive Screen (OCS)9 208 (NI) 71.1±14.5 11.5±2.7 6.6±4.69 days
OCS64 200 (I and H) 70.5±14.7 NI 6.1±4.4 days
Repeatable Battery for Assessment of 
Neuropsychological Status (RBANS)65
a) 158, b) 36 (NI) a) 64.27±14.45,  
b) 63.21±16.19
a) 34% < 12  b) 29% < 12 a) 20±19.4 days,  
b) 12 months
Rotterdam CAMCOG (R-CAMCOG)37 169 (I and H) 56.2±11.3 61.2% intermediate <12 months
Screening Instrument for Neuropsychological 
Impairments in Stroke (SINS)7
49 (I, IH, SH) 62±53.5 NI 38±17 days
Six-item Screener (SIS – by telephone)19 89 (NI) 62.9±8.6 9.2±4.2 > 3 months
Weigl’s Colour-Form Sorting Test (WCFT)66 105 (NI) 73.4±10.7 9.9±1.7 NI
Zürich Maxi Mental Status Inventory (ZüMAX)67 33 (NI) 63.2±14.7 NI 49.4±79.8 days
N: number of participants; NI: not informed; CVD: cerebrovascular disease; MI: multiple infarcts; SVD: small vessel disease; TIA: transient ischemic attack; I: ischemic; H: hemorrhagic; IH: 
intracerebral hemorrhage; SH: subarachnoid hemorrhage; VD: vascular dementia; aSAH: aneurysmal subarachnoid hemorrhage; SIVD: subcortical ischemic vascular disease.
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Table 2. Cognitive screenings,procedures for determining validity/reliability.
Cognitive screening
Procedures for determining validity/reliability  
with appropriate values 
Procedures for determining validity/
reliability without appropriate values 
Addenbrooke’s Cognitive Examination-
Revised (ACE-R)
SE/SP (relationships with criteria)13
Barrow Neurological Institute Screen 
for Higher Cerebral Functions (BNIS)
Concurrent validity (relation with criteria),27,28 SE (relation with 
criteria),27 convergent validity (relation with related constructs),27,28 
correlation (internal consistence reliability),27,28 comparison between 
contrasting groups (relation with criteria).28
SP (relation with criteria)27
Birmingham Cognitive Screen (BCoS – 
Cantonese version)
Inter-rater (internal-consistency reliability),29 test-retest (temporal 
stability reliability),29 comparison between contrasting groups (relation 
with criteria),29 convergent validity (relation with related constructs).29
Birmingham Cognitive Screen (BCoS) Comparison between contrasting groups (relation with criteria),30 
predictive validity (relation with criteria).30
Brief Memory and Executive Test 
(BMET)
Inter-rater (internal consistency reliability),31 test-retest (temporal 
stability reliability),31 SE/SP (relation with criteria),31 comparison 
between contrasting groups (relation with criteria),31 response times 
(response processes).31
Brief Neuropsychological Screening 
(BNS)
Comparison between contrasting groups (relation with criteria),32 
predictive validity (relation with criteria),32 convergent validity 
(relationship with related constructs). 32
Clock Drawing Test (CDT) SE/SP (relation with criteria)33 Convergent validity (relation with related 
constructs),7SE/SP (relation with criteria).7
Cog-4 Convergent validity (relation with related 
constructs),34 SE/SP (relation with criteria).34
Cognistat Convergent validity (relation with related 
constructs),7 SE/SP (relation with criteria).7
Cognitive Assessment Scale for Stroke 
Patients (CASP)
Convergent validity (relation with related 
constructs).35,36
Functional Independence Measure (FIM 
cognitive)
Convergent validity (relationship with related 
constructs)37
Middlesex Elderly Assessment of 
Mental State (MEAMS)
SE/SP (relation with criteria)38
Mild Vascular Cognitive Impairment 
Assessment tool for Stroke (MVCI)
Judge analysis - face validity (content-oriented evidence),39 convergent 
validity (relation with related constructs),39 SE/SP (relation with 
criteria),39 correlation,inter-rater (internal consistency reliability).39
Mini-Mental State Examination (MMSE) Comparison between contrasting groups (relation with criteria),16,24,41,45,46 
SE (relation with criteria),42SE/SP (relation with criteria),43,46 predictive 
validity (relation with criteria),24concurrent validity (relation with 
criteria),45convergent validity (relation with related constructs).16,45
SE/SP (relation with criteria),6 convergent 
validity (relation with related constructs),37,40 
predictive validity (relation with criteria),42,44 
SP(relation with criteria),42 SE (relation with 
criteria).24, 45
Montreal Cognitive Assessment (MoCA) Comparison between contrasting groups (relation with criteria), 
20,24,45,46,49,53,58,61SE/SP (relation with criteria),18,43,45,46,54,56,57,58,59,61 SE 
(relation with criteria), 12,24,48,49,62 SP(relation with criteria),20convergent 
validity (relation with related constructs),20,45,49,53,55,56,61 inter-
rater (internal-consistency reliability),20,55,61 predictive validity 
(relation with criteria),18,24,26,42concurrent validity (relation with 
criteria),45,53,61correlation (internal consistence reliability),55test-retest 
(temporal stability reliability). 55,61
Concurrent validity (relation with criteria),12,47 
SP(relation with criteria),12,42,48,49,62 SE (relation 
with criteria),20predictive validity (relation with 
criteria), 25,50convergent validity (relation with 
related constructs).59
miniMoCA SE/SP (relation with criteria),51convergent validity (relation with related 
constructs). 51
continues.
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Table 2. Cognitive screenings,procedures for determining validity/reliability (continuation).
Cognitive screening
Procedures for determining validity/reliability  
with appropriate values 
Procedures for determining validity/
reliability without appropriate values 
MoCA (by telephone) Comparison between contrasting groups (relation with criteria),19,60 
SE/SP (relation with criteria),19,52,60 convergent validity (relation with 
related constructs),60 concurrent validity (relation with criteria),60test-
retest (temporal stability reliability),60inter-rater (internal consistency 
reliability).60
Northwick Park Examination of 
Cognition (NPEC)
Comparison between contrasting groups (relation with criteria),63SE/SP 
(relation with criteria).63
Oxford Cognitive Screen (OCS) Convergent and discriminant validity (relation with related 
constructs),9SE/SP (relation with criteria),9 test-retest (temporal stability 
reliability),9 concurrent validity (relation with criteria),64 comparison 
between contrasting groups (relation with criteria).64
Repeatable Battery for Assessment of 
Neuropsychological Status (RBANS)
Convergent and discriminant validity (relation with related constructs),65 
predictive validity (relation with criteria).65
Rotterdam CAMCOG (R-CAMCOG) Convergent validity (relation with related constructs)37
Screening Instrument for 
Neuropsychological Impairments in 
Stroke (SINS)
Convergent validity (relation with related constructs)7 SE/SP (relation with criteria)7
Six-item Screener (SIS – by telephone) Comparison between contrasting groups (relation with criteria)19 SE/SP (relation with criteria)19
Weigl’s Colour-Form Sorting Test 
(WCFT)
Convergent validity (relation with related constructs),66 comparison 
between contrasting groups (relation with criteria).66
Zürich Maxi Mental Status Inventory 
(ZüMAX)
Comparison between contrasting groups (relation with criteria),67 test-
retest (temporal stability reliability).67
SE: sensitivity, SP: specificity.
25.45% included patients who were assessed from 3 to 
12 months post-stroke and 14.54% assessed patients 
more than 12 months post-stroke. A total of 9.09% of 
the articles did not report time post-stroke (Table 1). 
Psychometric properties of the instruments 
In the last few years, many studies have demonstrated 
the psychometric properties of the instruments 
according to the tripartite model of validity: content, 
criteria and construct. However, in our systematic 
review, we classified the evidence of validity and reli-
ability in accordance with recently established defini-
tions.21 Most of the studies determined validity based 
on relationships with criteria (60%), relationships with 
related constructs (22.50%), and content-oriented 
evidence (0.83%) (Table 2). Only 19 articles presented 
data on the reliability of the instruments, 10.83% of 
which discussed internal consistency reliability and 5% 
temporal stability reliability (Table 2). 
With respect to the procedures adopted to determine 
validity and reliability, many of the studies included a 
sensitivity and specificity analysis (28.33%), consid-
ered convergent validity (or relations to other tests) 
(21.66%), compared contrasting groups (14.16%), 
executed predictive validity (9.16%), performed inter-
rater analysis (7.5%), considered concurrent validity 
(5.83%), considered test-retest reliability (4.16%), tested 
for correlation with other measures (3.33%) and identi-
fied effect size (2.5%). The alternate form, discriminant 
evidence, response times and an analytical judgment of 
the instrument (face validity) were investigated once for 
each (0.83% overall). 
As can be observed in Table 2, the Montreal Cogni-
tive Assessment (MoCA) followed by the Mini-Mental 
State Examination (MMSE) were the instruments most 
analyzed to find validity and reliability evidence (40.90% 
and 18.18%, respectively). Other instruments were inves-
tigated once or twice per instrument. The studies were 
classified according to appropriate or inappropriate values 
present in the Discussion section of the articles (Table 2).
We found 26 instruments whose psychometric prop-
erties had been investigated in stroke patients (Table 3). 
Table 3 shows the neuropsychological functions evalu-
ated by the screening tools: episodic memory (80.77%), 
language (69.23%), orientation (65.38%), executive 
functions (61.54%), attention (53.84%), visuo-construc-
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Addenbrooke’s Cognitive Examination-Revised (ACE-R) X X X X X
Barrow Neurological Institute Screen for Higher Cerebral Functions (BNIS) X X X X X
Birmingham Cognitive Screen (BCoS) X X X X X X
Brief Memory and Executive Test (BMET) X X X X
Brief Neuropsychological Screening (BNS) X X X X X X X
Clock Drawing Test (CDT) X X
Cog-4 X X X X
Cognistat X X X X X X X
Cognitive Assessment Scale for Stroke Patients (CASP) X X X X X X
Functional Independence Measure (FIM Cognitive) X X X
Middlesex Elderly Assessment of Mental State (MEAMS) X X X X X
Mild Vascular Cognitive Impairment Assessment tool for Stroke (MVCI) X X X X X X X
Mini-Mental State Examination (MMSE) X X X X X X
MiniMoCA - Montreal Cognitive Assessment(miniMoCA) X X X X
Montreal Cognitive Assessment (MoCA) X X X X X
MoCA (by telephone) X X X X
MoCA (Hong Kong) X X X X
MoCA (Singaporean) X X X X X X X
Northwick Park Examination of Cognition (NPEC) X X X X X
Oxford Cognitive Screening (OCS) X X X X X X X
Repeatable Battery for Assessment of Neuropsychological Status (RBANS) X X X X
Rotterdam CAMCOG (R-CAMCOG) X X X X
Screening Instrument for Neuropsychological Impairments in Stroke (SINS) X X X
Six-item Screener (SIS) X X
Weigl’s Colour-Form Sorting Test (WCFT) X
Zürich Maxi Mental Status Inventory (ZüMAX) X X X X X X
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tion (38.5%), perception (34.61%), praxis (23.07%), 
abstraction (23.07%), arithmetic (19.23%) and process-
ing speed (3.84%). 
DISCUSSION
Characteristics of the samples
Regarding sample size, we identified wide variability 
in the number of participants, and only one study 
presented a sample calculation. Calculating the sample 
size in psychometric studies is recommended both to 
avoid finding differences between groups by chance and 
to increase the likelihood of detecting true, clinically 
significant differences.68 Therefore, the results of many 
papers should be interpreted with caution because they 
do not use representative samples of stroke patients. 
It is essential to ensure the sample’s representative-
ness by providing a detailed description of its sociode-
mographic and developmental characteristics in empiri-
cal studies.21 Most of the investigations involved elderly 
stroke patients (>60 years), and the psychometric 
properties of the screening are shown only for this age 
group. An increasing number of young people affected 
by this injury exhibit cognitive impairment, which is 
present in approximately 20% to 30% of young stroke 
patients.3 Age influences patient performance on cog-
nitive tasks.27,28,60 Therefore, it is important to verify 
whether validity and reliability evidence vary according 
to this variable for each test. 
Educational background may influence both patient 
performance and test sensitivity/specificity.1,9 However, 
several studies included in this review did not discuss 
the education of participants and did not control for 
this variable, which is a limitation.7,12,17,25,29,35,36,38,39,40,47,59, 
63,64,67,69 Adults with high educational levels usually have 
better performance on neuropsychological assessments, 
and the cut-off points of tests should take this into 
account.27,28,45,58,60,61 Years of education should always 
be considered in empirical studies in neuropsychology.
In relation to neurological variables, many studies 
did not report the cerebrovascular disease of the par-
ticipants (16.36%). Patients present vascular cognitive 
impairment regardless of stroke type,49 although there 
are differences in the neuropsychological performance 
of patients with vascular dementia (VD), subcortical 
ischemic vascular disease (SIVD) and mild cognitive 
impairment (MCI).45 Therefore, future studies could pro-
vide validity evidence and cut-off points for the screen-
ing according to cerebrovascular disease (when differ-
ences are found between groups). This would enable 
clinicians to know when significant deficits are present 
in each case.
Lastly, the time post-stroke is important to note in 
empirical studies because instruments have shown dif-
ferent cut-off points and because patients recover some 
neuropsychological functions approximately six months 
post-stroke.9,18,30,31,49,55,61 Neuropsychological assessment 
is indicated after acute stroke. The early recognition of 
cognitive deficits leads to improved interventions and 
thus prognosis.7 
Psychometric properties of the instruments 
Most instruments have shown validity regarding rela-
tionships with criteria, and the studies typically used 
age, education, stroke type and neuropsychological 
performance differentiations between clinical and 
control groups as criteria. This evidence is important in 
determining whether a neuropsychological instrument 
can predict either the performance of a specific group of 
individuals or whether there will be differences in the 
scores of contrasting groups.21 However, a stroke may 
produce different behavioral changes in individuals, 
thus complicating the definition of a criterion group. 
Although heterogeneity of performance is important 
for identifying the test’s psychometric properties, 
heterogeneity of lesions can limit the interpretation of 
the results for all types of cerebrovascular diseases. 
Evidence based on relationships with related con-
structs was also one the most common forms of validity 
evidence found by the screening. Correlation with other 
tests and measures (related constructs) is important for 
proving that an instrument assesses the intended cog-
nitive domains.21 In general, cognitive screening have 
been related with other instruments in that they evalu-
ate similar neuropsychological functions. However, the 
strength of the correlation between instruments varied 
widely due to the different characteristics of the tests. 
For example, the CASP showed weak correlation with 
MoCA and the MMSE likely because it has visual items 
that can be administered to patients with severe expres-
sive aphasia, while the other screening are language-
dependent.35 Therefore, interpreting evidence of valid-
ity based on conceptually related constructs should be 
carried out with caution.
Other psychometric procedures, such as seeking 
content validity, may not have been found frequently 
because most of the screening instruments were not 
specifically devised for stroke samples. Further evidence 
of validity should be found in the manuals of the tests 
published in each country. Our study is limited by a fail-
ure to describe these data.
Most of the studies analyzed only the validity – not 
the reliability – of the instruments. We suggest that 
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psychometric studies include analyses of reliability to 
enlarge their evidence and avoid measurement errors. 
For example, some studies with test-retest reliabil-
ity (temporal stability reliability) demonstrated that 
patients have better performance on the reevalua-
tion.9,18,33,34 Other studies show temporal score stabil-
ity.29,31,55,60,61,67 Several studies did not specify the time of 
cognitive evaluation.20,39,51,55,58,66 Therefore, future stud-
ies should clarify the timing of the evaluation and show 
evidence in accordance with this variable.
Regarding psychometric property procedures, sensi-
tivity and specificity analysis were the most commonly 
used in the studies. The sensitivity of a test relates to 
the percentage of individuals with deficits that the 
instrument is able to identify (true positive rate). In 
contrast, the specificity indicates the test’s ability to 
detect healthy people for the neuropsychological func-
tions measured (true negative rate). According to Blake 
et al.,70 a cognitive screening instrument should have 
values superior to 80% and 60% for good sensitiv-
ity and acceptable specificity, respectively. However, 
many screening instruments did not reach these val-
ues.6,7,14,19,20,24,27,38,42-45,48,61,62,66,69 Therefore, items need to 
be better studied and replaced to improve the quality of 
the instruments. 
Notably, convergent validity and comparisons 
between contrasting groups were frequently executed. 
These procedures are important to seek evidence of 
validity based on relationship with criteria, as pre-
viously discussed. Differences between contrasting 
groups with various degrees of severity of vascular 
cognitive impairment were highlighted in many stud-
ies.14,19,24,31,41,45,46,49,58,60,62,66 However, studies need to 
improve the control of variables such as sociodemo-
graphic (age and education) and neurological data (cere-
brovascular disease) that influence patient cognitive 
performance.4,46
In this review article, most cognitive screening 
used in stroke samples were originally developed to 
evaluate MCI and Alzheimer dementia patients, such 
as the MMSE, MoCA, WCFT, R-CAMCOG, ACE and 
CDT. However, there is no theoretical basis to justify 
the use of such screening, and they do not contain spe-
cific tasks for stroke patients. The application of neu-
ropsychological instruments with a theoretical base is 
important both to justify patient deficits and plan their 
rehabilitation. 
The NINDS and the CSN recommended the use of 
the MoCA to evaluate vascular cognitive impairment 
as an alternative to the MMSE.15 These instruments 
are correlated.20,45,55,56,61 However, one advantage of the 
MoCA is that the ceiling effects were substantially less 
evident than for the MMSE in stroke patients.14,24,26,62 
Although both instruments are commonly investigated, 
the applicability to stroke samples has been discus
sed.12,14,24,25,44,47-50,53,59,62 
Some studies support the high sensitivity 
of the MoCA18,46,51,54, but reveal its low specific-
ity.12,14,24,42,48,49,52,57,62 Chan et al.12 found that 77% of 
patients were classified as cognitively intact on the 
MoCA but were impaired for one or more cognitive 
domains on a neuropsychological assessment (intellec-
tual functioning, processing speed, and visual memory) 
not evaluated by the screen. The MoCA also failed to 
identify patients without problems in daily life function-
ing after mild stroke26,44,47,59 and discharge destination;50 
however, a relationship between the MoCA and func-
tional measures was found post-stroke.17,26
The MoCA has demonstrated wide validity and reli-
ability in several languages. However, researchers should 
exercise caution with MoCA cut-off points in each 
country because this test is influenced by educational 
level,45,58,60,61 age,60 cerebrovascular disease14,19,24,45,58,60 
and time post-stroke.49,57 Additionally, deficits in lan-
guage (comprehension and expression) and perception 
(hemineglect), which are common post-stroke, may 
negatively affect the performance of participants on 
MoCA tasks. 
A limitation of the studies on the MoCA is that the 
cut-off point for elderly samples without vascular dis-
ease, as well as cut-off points from different countries 
generally, to classify cognitive impairment patients,49 
underestimate the possible deficits post-stroke. It is also 
important to show cut-off points by subtest (cognitive 
function), which could contribute to understanding the 
impact of brain injury on specific skills.62
The MMSE is more specific than the MoCA,24,46 but 
is less sensitive for stroke patients.6,43,45 This instru-
ment can show differences between clinical and control 
groups16,17,41 and between various cerebrovascular dis-
eases,16,24,46 but underestimates cognitive impairment 
post-stroke.40 However, the MMSE has shown low pre-
diction ability for functional outcomes.44
According to Pendlebury et al.,14 the MMSE showed 
a ceiling effect in many subtests (naming, registration, 
reading and writing reaching near maximal scores) in 
amnestic, TIA and stroke groups. Moreover, the MMSE 
is insensitive for evaluating abstract reasoning, execu-
tive functioning, and visual perception/construction 
deficits that are present in subcortical lacunar strokes.6 
Compared to a detailed neuropsychological battery of 
tests, the MMSE did not present adequate levels of sen-
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sitivity and specificity.13 However, refining cut-off scores 
by age and education can both improve the sensitivity 
of the MMSE (at the cost of specificity).48
Studies that performed sensitivity/specificity analy-
ses with the MMSE showed that these values were no 
higher than 80%.42,43 As indicated by Stolwyk et al.,22 
these scores suggest that 20% of patients with vascular 
cognitive impairments are not identified, which is unac-
ceptable in clinical practice. Therefore, the MMSE is not 
recommended6,37 because it does not exhibit adequate 
psychometric properties for stroke patients. 
Other cognitive screening instruments developed for 
MCI and dementia have been tested in stroke samples, 
but none are specific for this population (CDT, WCFT, 
ACE, ACE-R, R-CAMCOG, MEAMS, Cog-4, SIS, SINS 
and RBANS). The psychometric properties of these 
instruments are weak and insufficient in clinical prac-
tice. The BNIS,28 ZüMAX67 and Cognistat7 are cognitive 
screening developed for acquired brain lesions in gen-
eral. The BNIS shows adequate psychometric proper-
ties,28 but does not measure neuropsychological func-
tions usually impairment post-stroke. In contrast, the 
ZüMAX and Cognistat present little evidence of validity 
in small stroke samples. Psychometric studies with these 
tests require further evidence of validity and reliability 
and should determine the optimal cut-off level for stroke 
patients.
This review study found only seven cognitive screen-
ing that are specifically designed to evaluate stroke 
patients: the BCoS, OCS, BNS, CASP, MVCI, BMET and 
NPEC. The BCoS assesses attention, executive func-
tion, language, memory, numeric abilities and praxis 
and exhibits wide validity and reliability.29,30 However, 
the BCoS has evidence only in the country in which it 
was developed, as well as for a Cantonese version. There-
fore, researchers from other countries (with different 
cultures and languages) should test it in their regions 
before applying it. The OCS is based on the BCoS and 
avoids the confounding effects of aphasia and neglect 
that are frequent in stroke patients.9,64 Demeyere et al.64 
showed higher sensitivity for the OCS than the MoCA in 
detecting cognitive impairments in stroke patients (88% 
vs. 79%). Future studies could build on the evidence of 
validity and reliability of this instrument, as well as pro-
vide broad normative data for other countries.
The format of the CASP appears better suited than 
the MMSE or MoCA for use in stroke patients with 
severe neurovisual disorders36 and aphasia because it 
can be administered without using language.35 However, 
its psychometric properties have yet to be studied.36 The 
BNS32 and NPEC63 discriminated acute stroke patients 
with cognitive impairments from those without cogni-
tive problems and can be used to determine different 
cognitive profiles according to the location of the lesion. 
The MVCI exhibits good validity and reliability, and the 
overall probability of correctly discriminating vascular 
cognitive impairment was 90.0%.39 The BMET correctly 
identified 78% of patients with cognitive impairment,31 
but was tested only in cerebral small vessel disease 
patients and shows modest sensitivity.
Impairments in reasoning and executive function-
ing are the most frequent cognitive deficits in the early 
phase post-stroke.6 Executive functions, attention and 
processing speed are also the most impaired functions 
in long-term stroke patients.5 However, most neuro-
psychological screening do not include tasks that evalu-
ate these functions because they are not developed for 
stroke patients, which justifies the construction of spe-
cific instruments. Moreover, the majority of the studies 
may underestimate patient deficits.
In summary, the psychometric properties of neuro-
psychological screening for stroke patients have been 
explored by initial analyses that did not use representa-
tive samples. Although the studies most frequently used 
the MMSE and the MoCA to find evidence of validity 
and reliability, the use of these instruments in stroke 
patients has been criticized due to their psychometric 
properties and the neuropsychological functions evalu-
ated. Therefore, more studies involving specific instru-
ments for stroke patients are necessary to confirm the 
validity and reliability of the cognitive screening.
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